title: Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function.
abstract: OBJECTIVE
  Recent data suggest that the administration of bone marrow-derived stem cells (BMSC) might improve myocardial perfusion and left ventricular (LV) function after acute myocardial infarction (AMI). The aim of this study was to assess spontaneous mobilization of BMSC expressing the haematopoietic and endothelial progenitor cell-associated antigen CD34+ after AMI and its relation to post-infarction remodelling.
  
  
  RESULTS
  Peripheral blood concentration of CD34+ BMSC was measured by flow cytometry in 54 patients with AMI, 26 patients with chronic stable angina (CSA), and 43 normal healthy subjects. In patients with AMI, LV function was measured by 2D-echocardiography. Eighteen AMI patients were reassessed at 1 year. BMSC concentration was higher in patients with AMI (mean peak value: 7.04+/-6.27 cells/microL), than in patients with CSA (3.80+/-2.12 cells/microL, P=0.036) and in healthy controls (1.87+/-1.52 cells/microL, P<0.001). At multivariable analysis statin use (P<0.001), primary percutaneous intervention (P=0.048) and anterior AMI (P=0.05) were the only independent predictors of increased BMSC mobilization after AMI. In the 28 patients without subsequent acute coronary events reassessed at 1 year follow-up, CD34+ cell concentration was an independent predictor of global and regional improvement of LV function (r=0.52, P=0.004 and r=-0.41, P=0.03, respectively).
  
  
  CONCLUSIONS
  AMI is followed by enhanced spontaneous mobilization of BMSC, in particular, in patients on statin therapy and following a primary percutaneous intervention. More importantly persistent spontaneous mobilization of BMSC might contribute to determine a more favourable post-AMI remodelling.
authors.affiliation: Institute of Cardiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy. antoniomarialeone@libero.it
authors.forename: Antonio Maria
authors.initials: AM
authors.lastname: Leone
authors.forename: Sergio
authors.initials: S
authors.lastname: Rutella
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Bonanno
authors.forename: Antonio
authors.initials: A
authors.lastname: Abbate
authors.forename: Antonio G
authors.initials: AG
authors.lastname: Rebuzzi
authors.forename: Silvia
authors.initials: S
authors.lastname: Giovannini
authors.forename: Mariaelena
authors.initials: M
authors.lastname: Lombardi
authors.forename: Leonarda
authors.initials: L
authors.lastname: Galiuto
authors.forename: Giovanna
authors.initials: G
authors.lastname: Liuzzo
authors.forename: Felicita
authors.initials: F
authors.lastname: Andreotti
authors.forename: Gaetano A
authors.initials: GA
authors.lastname: Lanza
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Contemi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000378:metabolism / Q000502:physiology*; D002465:Cell Movement / Q000502:physiology; D042783:Endothelial Cells / Q000378:metabolism / Q000502:physiology; D005260:Female; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000378:metabolism / Q000502:physiology; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D010641:Phenotype; D013234:Stem Cells / Q000378:metabolism / Q000502:physiology*; D018487:Ventricular Dysfunction, Left / Q000378:metabolism / Q000473:pathology; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D018952:Antigens, CD34